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Sixty-four patients with a history of ventricular tachy-
cardia and ventricular fibrillation refractory to conven-
tional therapy received aprindine to abolish recurrent
episodes of symptomatic ventricular tachycardia. Fifty-
six patients became asymptomatic and were followed up
for a mean period of 23 months. Aprindine dose was
adjusted to minimize adverse reactions but still control
arrhythmia. Survival analysis was performed for the
group with aprindine levels greater than 1.5 Ilg/ml and
The relation between antiarrhythmic drug blood levels and
the prevention of sudden cardiac death has been evaluated
by a number of studies over the past 12 years (1-5). Few
have conclusively demonstrated improved survival if the
level was in the therapeutic range. The Australian collab-
orative study (1,2) examined the value of phenytoin in pa-
tients after myocardial infarction. The number of deaths in
the treatment and control groups was similar, and later re-
view of blood levels did not appear to distinguish survivors
from nonsurvivors. A double-blind European study (3) ran-
domized survivors of myocardial infarction with arrhyth-
mias during convalescence (defined as peak frequency
>5/min multiform, repetitive or ventricular tachycardia) to
treatment with placebo or aprindine. No statistically sig-
nificant differences in mortality were noted.
In a small group of survivors of prehospital cardiac arrest,
Myerburg et al. (4) observed an improved outcome by those
survivors who maintained therapeutic blood levels of pro-
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the group with levelsof 1.5 Ilg/ml or less. At the end of
the study, 65% of the patients with a high level were
alive and asymptomatic as compared with only 35% of
the patients with a low level (p < 0.036). In patients at
risk of recurrent sudden cardiac death, high aprindine
levels maintained after abolition of symptomatic ven-
tricular tachycardia were associated with improved
survival.
(J Am Coli CardioI1985;5:738-43)
cainamide and quinidine. Greenspan et al. (5) also observed
early symptomatic recurrences in patients with ventricular
tachycardia having subtherapeutic procainamide levels in
contrast to asymptomatic subjects with blood levels in the
therapeutic range. These last two studies (4,5) suggest a
blood level-response relation.
We evaluated a group of survivors of ventricular tachy-
cardia and ventricular fibrillation treated with an investi-
gational drug, aprindine, solely from the viewpoint of drug
level and clinical response. Results from cardiac catheter-
ization, ambulatory electrocardiographic monitoring or elec-
trophysiologic testing were not taken into account.
Methods
Entry criteria. The study group was drawn from pa-
tients referred to the Johns Hopkins Hospital for evaluation
of ventricular arrhythmias. All patients met the following
criteria: I) an episode of sustained ventricular tachycardia
or ventricular fibrillation not associated with acute myo-
cardial infarction before entry; 2) failure of conventional
drug therapy (defined as continued episodes of ventricular
tachycardia despite drug doses sufficient to achieve thera-
peutic levels, toxic or allergic reactions or contraindication
such as a negative inotropic agent in the presence of heart
failure), 3) continued evidence of ventricular tachycardia
on ambulatory electrocardiographic monitoring, 4) treat-
ment with aprindine, and 5) initial control of symptomatic
ventricular tachycardia with aprindine.
Of the 64 subjects who met entry criteria I to 4, 8 failed
to meet criterion 5 and were excluded from statistical anal-
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ysis. These eight patients remained hemodynamically un-
stable from admissionto the hospital until death. This group
had received a series of drugs in addition to aprindine and
responded to none. As a result of continued manipulation
of various drug regimens, no drug level was considered
stable.
Study pat ients (Table 1). The study group included 56
subjects with a mean age of 51 years; 86% of the patients
were male. Before entry. 33 had symptomatic ventricular
tachycardia and 23 had ventricular fibrillation . The cardiac
diagnoses includedcoronary artery disease (63%). nonisch-
emic cardiomyopathy (2 1%), both coronary artery disease
and cardiomyopathy (5%) and valvular disease, congenital
heart disease or no detectable cardiac abnormality (11%).
More than half of the subjects had heart failure (54%)
or prior myocardial infarction (59%). The response to ther-
apy was considered good if the patient remained asymp-
tomatic. Failure was defined as sudden death or recurrent
syncope associated with ventricular tachycardia or ventric-
ular fibrillation . By the end of the study in 1981 , 16patients
had died suddenly, 4 had recurrentsyncope and 36 remained
asymptomatic. The mean follow-up period was 23 months
(range 2 to 51 ). There were no statistically significant dif-
ferences in the distribution of sex. age, entry arrhythmia,
cardiac diagnosis or clinical characteristics among the study
patients.
Investigational drug protocol . Aprindine, an investi-
gational agent with a long half-life. permits less fluctuation
and variability in overall blood level. Electrophysiologi-
cally, it resembles quinidine. It slowsconduction andlengthens
the refractory period of the atria. ventricles and atrioven-
tricular (AV) node (6-10). His-Purkinje conduction time
lengthens with aprindine, but spontaneous sinus node dis-
charge shows little decrease. Aprindinewas previously used
Table 1. Demographic Characteristics of 56 Study Patients
Aprindine Levels"
:51.5 JLg/ml > 1.5 ILg/ml Total
Sex
Men 18 30 48
Women 3 5 8
Mean age (yr) 49 51 51
Entry arrhythmia
Ventricular tachycardia 16 17 33
Sudden deathiventricular fibrillation 5 18 23
Cardiac diagnosis
Coronary artery disease 9 26 35
Nonischemic cardiomyopathy 7 5 12
Both 2 I 3
Other 3 3 n
Clinical characteristics
Heart failure 12 18 30
Prior myocardial infarction 9 24 33
*Differences in distribution between low (:51.5 ILg/ml) and high
( > 1.5 ILg/ml) aprindine levels not significant by chi-square analysis.
in patients with the Wolff-Parkinson-White syndrome (I I)
and ventricular arrhythmias (12-14) before the recent ter-
mination of investigations because of a high incidence of
adverse reactions. particularly agranulocytosis. No patient
in the current study experienced this complication.
Patients were initially evaluated in the coronary care unit.
where they usually remained 5 to 7 days until arrhythmia
control was achieved. Thereafter, they were continuously
monitored in the clinical research inpatient unit. Aprindine
hydrochloride was administered either intravenously or
orally, depending on the clinical urgency for treatment.
Patients with an unstable hemodynamic status requiring im-
mediate correction of ventricular tachycardia received 200
mg intravenously at a rate of 2 mg/min. If the response was
only partial (for example. conversion of sustained to non-
sustained ventricular tachycardia), additional aprindine up
to a maximal of 400 mg in 24 hours was administered if
tolerated. Oral loading included 200 mg daily in divided
doses for 2 days. The initial maintenance dose was 75 mg
twice daily. The final maintenance dose ranged from 25 to
75 mg twice daily.
Dose regulation. The first goal of clinical dose adjust-
ment was the abolition of episodes of symptomatic ventric-
ular tachycardia. which has previously caused syncope, hy-
potension. dizziness or palpitation. Second, an attempt was
made to suppress asymptomatic ventricular tachycardia if
noted on ambulatory electrocardiographic monitoring. This
was accomplished by increasing the aprindine dose as tol-
erated. The dose was decreased if any intolerableside effects
were observed by monitoring for symptoms of tremor, ataxia.
dizziness, inability to concentrate and any abnormal labo-
ratory results, particularly depression of granulocytes.
Ambulatory electrocardiographic monitoring was per-
formed after treatment with aprindine and repeated at 3 to
6 month intervals. Patients were reevaluated if they had
symptoms of recurrent arrhythmia. This study was a clinical
trial of aprindine monitored by symptomatic response and
noninvasive evaluation. Electrophysiologic testing was not
employed to guide therapy.
Drug levels. Serum levels of aprindine were measured
using a Shimadzu GC-3BF gas chromatograph and a pre-
viously described assay (15 ) . Serum samples. run in du-
plicate. wereobtained immediately before an expected dose
for measurement as the aprindine hydrochloride concentra-
tion (j.Lg/ml). The patients' serum was compared with in-
ternal standards and aprindine stock solution.
It took approximately I month to complete the start of
the therapy. adjustments of dose and achievement of steady
state. This period takes into account the initial loading pe-
riod, the initial maintenance period and the time required
for downward titration to minimize central nervous system
side effects. We chose the level at I month to exclude any
question about manipulation of drug dosage. The drug level
at this time was defined as the initial blood level. On the
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Elapsed Days Since Entry into Study
Figure 2. Survival curve for initial study group of 56 patients
using the initial blood level drawn after day 25. The proportion
of patients remaining alive and asymptomatic is demonstrated for
the patients with high and low aprindine levels.
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the high aprindine group of 27 patients (level> 1.5 I-tg/ml),
with the median time to this event being 665 days. Five
deaths or episodes of syncope occurred in the low aprindine
group of 15 patients (level:::=; 1.5 I-tg/ml), with the median
time to this event being 226 days. The outcome experience
of the two survival curves is significantly different
(p <0.04). Although similar survival seems to occur at
1,000 days, fewer subjects were being followed up on the
lower curve. At 300 days of follow-up, 12 patients had an
aprindine level greater than 1.5 I-tg/ml compared with only
2 patients with an aprindine level of 1.5 I-tg/ml or less.
Survival experience for the entire study group of 56
patients with initial blood levels of aprindine determined
after day 25 and 14 determined after day 50 (Fig. 2). Ten
deaths or episodes of syncope occurred in the high aprindine
group of 35 patients (> 1.5 I-tg/ml), with the median time
Figure 1. Survival curve for the 42 patients with initial blood
levels drawn between days 25 and 50. The proportion of patients
remaining alive and asymptomatic is demonstrated for the patients
with high and low aprindine levels.
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42 Patients: predose sample 5/15 7/27
days 25 and 50
14 Patients: predose sample 5/6 3/8
after day 50
Total (56 patients) 10/21 (48%) 10/35 (29%)
Results
Clinical response (Table 2). The initial blood level was
obtained between days 25 and 50 in 42 patients. It was
obtained after day 50 in an additional 14 patients but later
than day 180 in only 2 patients. Twelve deaths or episodes
of syncope occurred among the 42 patients whose initial
blood level was obtained between days 25 and 50: 5 among
the 15 patients with a low aprindine level and 7 among the
27 patients with a high aprindine level. In the entire group
of 56 patients, 20 deaths or episodes of syncope occurred:
lOin the low aprindine group and lOin the high aprindine
group.
Survival experience for 42 subjects with initial blood
levels of aprindine determined between days 25 and 50
(Fig. 1). Seven deaths or episodes of syncope occurred in
Table 2. Numberof Deaths or Episodes of Syncope
Initial Aprindine
Blood Level*
*Distribution of therapeutic failures (death or syncope) in 56 study
patients grouped acccording to initial blood level.
basis of the distribution of levels, subjects were classified
into two groups: those whose aprindine level was greater
than 1.5 I-tg/ml and those whose aprindine level was 1.5
I-tg/ml or less. This classification at 1.5 I-tg/ml was chosen
on the basis of a retrospective analysis of the data. It per-
mitted two groups for statistical comparison and was in the
center of the empirically defined therapeutic range of I to
2 I-tg/ml.
Statistical analysis. The high (> 1.5 I-tg/ml) and low
(:::=; 1.5 I-tg/ml) aprindine groups were examined for any dif-
fering distribution of underlying risk factors that might in-
fluence outcome such as sex, number of infarcts, congestive
heart failure, angina, diabetes, hypertension, smoking, a
family history of sudden cardiac death, ejection fraction and
left ventricular end-diastolic pressure. No significant dif-
ference in the distribution of these risk factors was observed
between the high and low aprindine groups. The relation
between initial aprindine blood levels and the probability
of death or syncope was examined and tested by Kaplan
Meier survival plots (16) and the generalized Wilcoxon test.
One month blood levels in 14 patients were obtained after
day 50 and for these subjects drug level is confounded with
outcome; therefore, all analyses were performed including
and excluding these subjects.
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*Variability of aprindine blood levels over duration of study.
to this event being 597 days. Ten deaths or episodes of
syncope occurred in the low aprindine group of 21 patients
(:S 1.5 p,g/ml), with the median time to this event being 257
days. At the end of the study, the proportion alive and
asymptomatic in the high aprindine group was 65% as com-
pared with 35% in the low aprindine group. The outcome
experience of patients with the high aprindine level appears
to be associated with improved survival.
Variability of aprindine blood levels over time.
Although the prediction of survival was based on the initial
aprindine level, a final level was evaluated to determine
variability of levels over time (Table 3). Some variability
is expected as a result of change in prescribed dosage, dose
actually taken, difference in the time the blood sample was
obtained relative to the last dose, possible malabsorption
and altered bioavailability of different lots of the drug.
The mean final blood level was defined as the last level
drawn at the close of the study or the last level before
death. For both sets of patients, the mean final level was
slightly lower than the mean initial blood level (Fig. 3). For
the majority of subjects, the decrease represents the neces-
sity of lowering the dose because of adverse central nervous
system effects. At the time of the final blood level deter-
mination, the classification (high versus low aprindine blood
level) was changed in a number of cases. Consequently,
calculation of mean initial and mean final blood levels for
the high and low aprindine groups individually would be
statistically invalid.
We evaluated any classification change at the timeof the
final blood level determination. Nine patients with an initial
level of 1.5 p,g/ml or less had a high final aprindine blood
level. In seven of these subjects, aprindine dosage was in-
creased in the recent or immediate past because asympto-
matic ventricular tachycardia was seen on ambulatory
electrocardiographic monitoring. Two subjects had a level
near the 1.5 p,g/ml division, which altered their classifi-
cation but produced little overall change. In this subset of
nine patients, the three subjects who died suddenly also had
clinical evidence of progression of their underlying heart
disease.
Nine patients with an initial blood level of greater than
1.5 p,g/ml had a low final aprindine blood level. In three
of these subjects, no clinical explanation was available. One
subject had a level near the 1.5 p,g/ml division, which al-
tered the classification but produced little overall change.
In two subjects, the lower aprindine blood level reflected
dosage regulation due to adverse effects. Three subjects died
Table 3. Aprindine Blood Levels (jLg/ml)*
finalinitial
2.0
o ......------- ..J
3.0
4.0 _--_-----_--..,
1.0
suddenly: one who stopped taking aprindine, one with a
low postmortem drug level and one whose blood level changed
when switching from the intravenous to the oral form of
aprindine. The latter three events provide the strongest evi-
dence for maintaining a "therapeutic" blood level.
Figure 3. Initial and final aprindine levels in 54 patients.
Discussion
This study was designed to assess the ability of the anti-
arrhythmic drug blood level to influence and predict the
clinical response. Although all patients left the hospital with-
out symptomatic ventricular tachycardia, improved survival
was observed when the aprindine blood level exceeded 1.5
p,g/ml. This relation was suggested by the subset of 42
subjects whose blood level was obtained during a specific
time period (Fig. I); it was reinforced when the entire study
group of 56 subjects using all initial blood levels was con-
sidered (Fig. 2). During a 3 year follow-up, subjects with
a high aprindine blood level had a 65% survival rate in
comparison with 35% for the low aprindine group.
Methodologic considerations. This study did not ran-
domly assign patients to a high or low aprindine group, but
rather used clinical improvement (abolition of recurrent ep-
isodes of symptomatic ventricular tachycardia) and adjust-
ment of dosage to avoid serious adverse effects as end points
of drug manipulation. The study did not have a control group
who received placebo since it would have been considered
unethical in survivors of sudden death with risk of recur-
rence. Although randomization and placebo controls are
desirable ideals, they are often difficult to achieve in clinical
medicine. Certainly, dosage adjusted by symptoms and by
0.024
0.1
p Value
1.65
1.73
Mean Final Level
2.0t
1.96
Mean Initial Level
42 Patients
56 Patients
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an attempt to suppress asymptomatic ventricular tachycardia
is not unreasonable. In the future, electronic devices, such
as antitachycardia pacemakers or automatic defibrillators
providing' 'backup" therapy, may make it possible to utilize
a placebo control group. At the present time, drug therapy
may also be guided by the response to electrophysiologic
testing, with maintenance of the drug level achieved when
the arrhythmia is suppressed. Data are available to suggest
clinical efficacy of treatment despite the continued presence
of ventricular ectopic beats (17), although abolition of
asymptomatic ventricular tachycardia in a group of survivors
of symptomatic ventricular tachycardia was associated with
a better outcome (18).
There were no statistically significant differences be-
tween the high and low aprindine groups (Table I). It should
be recognized that differences might emerge if the sample
size were larger. Although the univariate predictors of poor
outcome were distributed equally among the two groups, it
is possible that low drug levels reflect other unmeasured
variables that could have influenced outcome. The aprindine
dose level is not a controlled variable and, thus, a causal
relation to death or syncope is not confirmed. Nevertheless,
the improved outcome and the elimination of an implied
mechanism of death (ventricular arrhythmia) do not seem
unreasonable to support a relation between drug level and
survival.
One criticism of this study is its exclusion of eight sub-
jects who never achieved control of symptomatic ventricular
tachycardia and who were in hemodynamically unstable
condition. Their changing drug regimens did not allow a
stable state of any agent. Thus, they cannot be considered
as a group for comparison even though six of the eight had
an aprindine level exceeding 1.5 /log/ml. All had extremely
severe heart disease, which was the major factor affecting
their mortality. Six of the eight patients underwent cardiac
catheterization and two died before study. Five of the six
patients had near total to total obstruction of the proximal
left anterior descending coronary artery and the sixth had
total obstruction in the midportion of the left anterior de-
scending coronary artery. Five of the six patients had severe
left ventricular dysfunction. Thus, survival in this group
might have been expected to be exceptional, regardless of
ventricular arrhythmias.
Blood level sampling. The day and time of blood level
sampling is critical. Predose samples are chosen for analysis
since this time is close to the nadir of the drug level. Blood
level rather than dosage was emphasized because of the
importance of the former. The initial blood level in this
study was not obtained before day 25 because of the ne-
cessity of dose adjustments to control the arrhythmia and
minimize side effects. Steady state was not achieved during
adjustment as a result of the long half-life of the drug. As
stated by Winkle (19), dose adjustment alone is not an
important factor in determining the outcome of a clinical
trial, but it should occur early in the study.
Conclusions. There was a narrow toxic-therapeutic range
for aprindine, which limited its usefulness. Variability of
blood levels over time did occur, quite often because of the
necessity of dose reduction due to adverse central nervous
system effects. These problems in addition to the high in-
cidence of agranulocytosis resulted in the suspension of
investigations. Nevertheless, some patients with refractory
ventricular arrhythmias did derive benefit from the drug.
The data, however, are presented not to resurrect aprindine,
but rather to demonstrate the potential value of antiar-
rhythmic levels in a "therapeutic" range.
The results of the present study may not be applicable
to other antiarrhythmic drugs, nor to all patients with ven-
tricular arrhythmias. Entry into this study required that par-
ticipants be survivors of sustained ventricular tachycardia
or ventricular fibrillation. Nevertheless, with maintenance
of a drug level that suppresses symptomatic ventricular
tachycardia, it would seem reasonable to expect continued
protection unless there is a change in the underlying cardiac
abnormality. This conclusion is similar to those in previous
studies (4,5) showing improved survival with "therapeutic"
levels of procainamide and quinidine. Thus, while there is
still no large scale study demonstrating efficacy of thera-
peutic levels of antiarrhythmic drugs to prevent sudden death,
the present investigation supports the importance of the blood
level in the management of patients with serious ventricular
arrhythmias.
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